<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04648696</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00069815</org_study_id>
    <nct_id>NCT04648696</nct_id>
  </id_info>
  <brief_title>Safety and Outcomes Associated With Continuous Versus Intermittent Infusion Vancomycin</brief_title>
  <official_title>Safety and Outcomes Associated With Continuous Versus Intermittent Infusion Vancomycin in Outpatient Parenteral Antibiotic Therapy: a Prospective, Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the safety and outcomes associated between the two treatment modalities&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Assess the risk of vancomycin-associated nephrotoxicity and outcomes associated with&#xD;
      continuous infusions (CI) versus II dosing in the outpatient parenteral antibiotic therapy&#xD;
      (OPAT) setting&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 3, 2021</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>To assess the risk of vancomycin-associated nephrotoxicity and outcomes associated with continuous infusions (CI) versus II dosing in the outpatient parenteral antibiotic therapy (OPAT) setting</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Nephrotoxicity</measure>
    <time_frame>week 8</time_frame>
    <description>Any increase in Serum creatinine by 50% from baseline, an increase in Scr by 0.5 mg/dL, or an increase in Scr by 0.3 mg/dL on two consecutive measurements</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Leukopenia</measure>
    <time_frame>week 8</time_frame>
    <description>White Blood Cell (WBC) &lt; 4,000 x 103 cells/µL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Infusion-related reactions</measure>
    <time_frame>week 8</time_frame>
    <description>Flushing/Erythema /Rash/Red Man Syndrome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of serum vancomycin measurements within therapeutic range</measure>
    <time_frame>week 8</time_frame>
    <description>CI goal - area under the curve (AUC)/minimum inhibitory concentration (MIC)400 - 600 mg x hr/L (a vancomycin random within 16.7 and 25.0 mcg/mL will correlate with this range)&#xD;
II goal - If inpatient dose was determined by AUC monitoring: A vancomycin trough that is within 3.0 mcg/mL of the trough that correlated with a therapeutic AUC based on inpatient monitoring - If inpatient dose was not determined by AUC monitoring or vancomycin was initiated as outpatient: A vancomycin trough of 10.0 - 20.0 mcg/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Resolutions of symptoms associated with the infection</measure>
    <time_frame>week 8</time_frame>
    <description>No need for additional induction therapy beyond the planned end date</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Treatment Failures</measure>
    <time_frame>week 21</time_frame>
    <description>Persistence, new onset, or worsening local or systemic signs and symptoms of infection</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Infection</condition>
  <arm_group>
    <arm_group_label>continuous infusions (CI) group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CI group will have their total daily cumulative dose of vancomycin converted to a 24-hour intravenous infusion upon discharge</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intermittent infusion (II) group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Inpatient study candidates that are randomized to the II group will continue their current intravenous dosing upon discharge</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin CI</intervention_name>
    <description>The CI group will have their total daily cumulative dose of vancomycin converted to a 24-hour intravenous infusion upon discharge - the CI will begin with the first scheduled OPAT dose of vancomycin</description>
    <arm_group_label>continuous infusions (CI) group</arm_group_label>
    <other_name>glycopeptide antibiotic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin II</intervention_name>
    <description>Study candidates that are randomized to the II group will continue their current intravenous dosing upon discharge</description>
    <arm_group_label>Intermittent infusion (II) group</arm_group_label>
    <other_name>glycopeptide antibiotic</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients at least 18 years of age&#xD;
&#xD;
          -  Receiving Wake Forest Baptist Health OPAT services&#xD;
&#xD;
          -  Will receive vancomycin therapy from Wake Forest Baptist Health Specialty Home&#xD;
             Infusion Pharmacy&#xD;
&#xD;
          -  Planned therapy with vancomycin in the outpatient setting for at least 2 weeks in&#xD;
             duration&#xD;
&#xD;
          -  Prescribed vancomycin with a frequency of either every 12 hours or every 8 hours&#xD;
             dosing at the time of enrollment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of diseases or conditions known to affect the pharmacokinetics of vancomycin:&#xD;
&#xD;
        Pregnancy/Ascites/Burn injury/Cystic fibrosis /Weight greater-than or equal-to 150 kg&#xD;
&#xD;
          -  Pre-existing leukopenia:&#xD;
&#xD;
        WBC &lt; 4,000 x 103 cells/µL&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Williamson, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest Health Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zachary P Gruss, PharmD</last_name>
    <phone>704-609-7694</phone>
    <email>zgruss@wakehealth.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Wake Forest Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zachary P Gruss, PharmD</last_name>
      <phone>704-609-7694</phone>
      <email>zgruss@wakehealth.edu</email>
    </contact>
    <investigator>
      <last_name>John Williamson, PharmD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 23, 2020</study_first_submitted>
  <study_first_submitted_qc>November 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 1, 2020</study_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>infusion therapy</keyword>
  <keyword>continuous infusions</keyword>
  <keyword>nephrotoxicity</keyword>
  <keyword>outpatient parenteral antibiotic therapy</keyword>
  <keyword>vancomycin</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Vancomycin</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

